Background
Ref | Age | Stage | Size (cm)/ Laterality | Associated component | Operation | Chemotherapy | Follow-up |
---|---|---|---|---|---|---|---|
1. [10] | 27 | Ia | 11/left | None | LSO/ROVBx/OM/AP/PALA/peritoneal Bx | TC | NED10 m |
2. [11] | 64 | Ia | 14/right | None | TAH/BSO/OM | BEP | NED 9 m |
3. [12] | 73 | IV | 9/left | None | TAH/BSO/OM/nephrectomy/resection of brain metastasis | TC → γ -knife | NED 12 m |
4. [6] | 64 | IV | 11/right | None | BSO/TAH/OM/peritoneal Bx | TC (neo adjuvant) | NED 64 m |
5. [13] | 40 | IIIc | 15/left, 7/right | None | BSO/OM//PALA/bladder and sigmoid colon deposit excision | EP | NED 6 m |
6. [14] | 50 | IV | 25/left | None | BSO/TAH/partialOM/AP | TC | DOD 3 m |
7. [15] | 35 | IIIc | 6/left | None | TAH/BSO | No | AWD 3 m |
8. [16] | 44 | IIIc | 9/right | None | TAH/BSO/OM | Yes | DOD 22 m |
9. [17] | 76 | IIb | 35/eft | None | TAH/BSO/OM | No | DOD post op |
10. [18] | 77 | IV | 15/unclear | None | Palliative surgery | Etoposide&carboplatin | DOD 1.5 m |
11. [18] | 58 | Ia | Unclear/left | None | TAH/BSO/LM/OM | TP → taxotere | DOD 17 m |
12. [18] | 67 | III | 13/left | None | TAH/BSO/LM/OM/PALA/peritoneal Bx | TC | NED 5 m |
13. [19] | 75 | IV | 13/right | None | TAH/BSO/LM/OM/PALA/peritoneal Bx | Etoposide&carboplatin →TC | NED 36 m |
14. [20] | 46 | III | 12/right | None | TAH/BSO/OM | No | DOD 4 m |
15 present case | 70 | IIIc | 20/right | None | TAH/BSO/OM | EP | NED 3 m |
16. [21] | 71 | IIIb | 6.5/right | Serous carcinoma | TAH/BSO | TC | NED 8 m |
17. [22] | 47 | Ic | 11/unclear | Serous adenocarcinoma & malignant brenner tumor | TAH/BSO/LM/OM/AP/PALA | TP | NED 24 m |
18. [23] | 68 | IIIc | 7/right, 5/left | Serous adenocarcinoma with focal mucin secretion | BSO/OM | TC → Doxil | DOD 7 m |
19. [24] | 44 | Ia | 25/left | Mucinous intraepithelial adenocarcinoma | TAH/BSO/OM | TC | DOD 4 m |
20. [2] | 45 | Ib | 18/right | Mucinous cystadenoma (BLM) & partial intraepithelial carcinoma | TAH/BSO/OM | Yes | DOD 36 m |
21. [2] | 58 | IIIb | 30/left | Mucinous cystadenoma (BLM) & partial intraepithelial carcinoma | TAH/BSO/OM/AP/LM/peritoneal Bx | Yes | DOD 8 m |
22. [25] | 34 | Ic | 16/left | Mucinous cystadenoma (BLM) & mucinous adenocarcinoma | TAH/BSO/OM | CP | DOD 8 m |
23. [3] | 22 | I | 21/right | Mucinous tumor (BLM) & mucinous adenocarcinoma | RSO/AP | CP | DOD 3 m |
24. [4] | 22 | Ia | 21/right | Mucinous cystadenoma (BLM) & mucinous adenocarcinoma | RSO/AP | CP | DOD 3 m |
25. [3] | 55 | I | 26/right | Mucinous tumor (BLM) & intraepithelial carcinoma | TAH/BSO | Pt-based chemotherapy | NED 68 m |
26. [3] | 55 | III | 13.5/right | Mucinous tumor (BLM) | TAH/BSO | Pt-based chemotherapy | DOD 2 m |
27. [26] | 18 | IV | 10/unclear | Mucinous tumor (BLM) | TAH/BSO/OM/LM/PALA /prior oophorocystectomy | TC | DOD7m |
28. [3] | 54 | I | 14/right | Mucinous & endometrioid carcinoma | TAH/BSO | Pt-based chemotherapy | NED 66 m |
29. [9] | 50 | Ia | 15/right | Mucinous adenoma | TAH/BSO/LM/OM | EP → TC | DOD 7 m |
30. [27] | 65 | Ia | 16.5/left | Mucinous adenoma | TAH/BSO/LM/OM/AP | No | DOD10m |
31. [28] | 35 | Ic | Unclear | Mucinous adenoma | TAH/BSO/OM | Pt-based chemotherapy | NED 120m |
32. [29] | 68 | IV | 20/left | Adenocarcinoma | TAH/BSO/LM/OM | Etoposide&carboplatin, palliative radiation therapy | DOD 7 m |
33. [3] | 39 | IV | 5/right | Mucinous adenocarcinoma | TAH/BSO | Pt-based chemotherapy | AWD 8 m |
34. [24] | 73 | IIIc | 11/left | Mucinous micro invasive adenocarcinoma | BSO/OM/LM(Bx)/prior TAH | TP | DOD 8 m |
35. [3] | 59 | I | 14/ left | Adenocarcinoma, NOS | BSO | Pt-based chemotherapy | NED 28 m |
36. [30] | 35 | III | 15/right | Mucinous cystadenoma (BLM) & mucinous adenocarcinoma | TAH/BSO/OM/AP | Yes | DOD 4 m |
37. [31] | 40 | Ia | 30/left | Mucinous adenoma, cystadenoma (BLM) & mucinous adenocarcinoma | TAH/BSO/LM/OM/AP/PALA | Yes | NED 8 m |
38. [32] | 21 | Ia | 5/right | Mucinous tumor (BLM) | RSO | BEP → TC | DOD 5 m |
39. [33] | 70 | Ia | 16/right, unclear/left | Mucinous tumor (BLM) | TAH/BSO/LM/OM/AP | No | NED 6 m |
40. [34] | 48 | I | 15/right | Mucinous cystadenoma (BLM) & mucinous adenoma | TAH/BSO/LM/OM | No | NED 3 m |
41. [35] | 36 | IIIc | 26/right | Mucinous endocervical tumor (BLM)& intraepithelial carcinoma | TAH/BSO/LM/OM | Yes | NED 6 m |
42. [6] | 65 | Ic | 15/left | Endometrioid adenocarcinoma & squamous differentiation mucinous adenocarcinoma | TAH/BSO/OM | TC | DOD 2 m |
43. [6] | 80 | IIc | 7/left | Endometrioid adenocarcinoma | TAH/BSO/PLA/OM/AP | TC | NED 40 m |
44. [6] | 42 | IIIb | 13/left, unclear/right | Endometrioid adenocarcinoma | TAH/BSO/PLA/OM/PALA | TC | NED 32 m |
45. [2] | 77 | Ia | 15/unclear | Endometrioid adenocarcinoma | TAH/BSO/LM/peritoneal Bx | No | DOD 19 m |
46. [36] | 33 | Ic | 11/left | Endometrioid adenocarcinoma | LSO/ROVBx/partial OM | Camptosar | DOD 6 m |
47. [3] | 53 | III | 14.5/left | Endometrioid adenocarcinoma | TAH/BSO | Pt-based chemotherapy | NED 37 m |
48. [3] | 63 | IV | 14/left | Endometrioid adenocarcinoma | TAH/RSO | Pt-based chemotherapy | DOD 9 m |
49. [37] | 49 | III | 4.6/left | Endometrioid adenocarcinoma | TAH/BSO/LM/OM/peritoneal Bx | Yes | NED 4 m |
50. [38] | 53 | I | 21/left | Mucinous tumor (BLM), invasive mucinous adenocarcinoma & teratoma | TAH/BSO/LM/OM | EP | DOD 7 m |
51. [38] | 53 | IV | 20/left | Mucinous tumor (BLM), invasive mucinous adenocarcinoma & teratoma | TAH/BSO/LM/OM/peritoneal Bx | TC | DOD 5 m |
52. [3] | 47 | III | 14/right | Adenocarcinoma, teratoma & NOS | TAH/BSO | Pt-based chemotherapy | NED 11 m |
53. [28] | 56 | IIc | 18/right | Mucinous carcinoma & teratoma | TAH/BSO/peritoneal Bx/PLA | No | DOD 10 m |
54. [16] | 56 | Ic | 18/right | Mucinous adenocarcinoma & teratoma | TAH/BSO/LM | No | DOD 10 m |
55. [3] | 25 | IV | 5/right | Teratoma | BSO/OM/AP | Pt-based chemotherapy | DOD 36 m |
56. [39] | 69 | IV | 15/left | Teratoma | LSO/thoracic Bx | TC | DOD 6 m |
57. [39]. | 54 | III | Unclear | Teratoma | TAH/BSO/ sigmoid resection | Yes | NED 12 m |
58. [3] | 42 | IV | Unclear | Benign cyst & teratoma (contralateral ovary) | TAH/BSO | Pt-based chemotherapy | DOD 20 m |
Case presentation
Methods
Discussion
Origins
Differential diagnosis
Differential diagnosis | Pathological features |
---|---|
LCNEC | |
Primary or metastatic carcinoid tumor | Uniform cell with rare mitotic figure and inexistent necrosis [17]. |
SCC pulmonary type | Smaller cell with obvious necrosis and less-intense immunohistochemical reactivity for CK and CgA. [30]. |
SCC hypercalcemic type | |
Metastatic neuroendocrine carcinoma | |
Non-neuroendocrine tumors with neuroendocrine differentiation |